Ease of Use of the Lebrikizumab Prefilled Pen for Individuals with Atopic Dermatitis
Patient Preference and Adherence · 2026-07 · Volume 20 · 1-9
DOI: 10.2147/ppa.s612056 ↗Kurz gefasst
Fachartikel in der Zeitschrift Patient Preference and Adherence, 2026-07. Verfasst von Jennifer Soung und 9 weiteren Autor:innen. Beteiligte Einrichtung: Southern California Dermatology, Santa Ana, CA, USA. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Background
Atopic dermatitis (AD) is a chronic inflammatory skin disease that can require long-term systemic therapy in individuals with moderate-to-severe disease. Lebrikizumab is a monoclonal antibody that targets interleukin 13, an important cytokine involved in AD pathogenesis. A single-use, prefilled pen has been developed to enable self-injection, and its usability is the focus of this study. Because ease of use and user confidence are considered important factors in self‑injection experiences, evaluating the usability of injection devices is an important component of patient-centered care. This study assessed the usability of the lebrikizumab prefilled pen in adults with AD in a simulated injection setting using a validated patient-reported questionnaire.
Methods
In this open-label, single-site, single-visit simulated injection study (NCT06444165), 55 adults with AD performed a simulated injection using a relabeled commercial lebrikizumab prefilled pen (250 mg/2 mL) after training. The injection was performed into an injection pad designed to mimic skin tissue. Participants completed the modified Subcutaneous Administration Assessment Questionnaire (mSQAAQ), a 10-item instrument assessing ease of use and confidence. The primary endpoints were responses to 2 questions: "Overall, easy to use" and "Confidence in ability to use the device." All analyses were descriptive.
Results
Among 55 participants, 96.4% agreed or strongly agreed that the pen was "overall, easy to use", and 96.4% agreed or strongly agreed they were "confident in their ability to use the device" based on the mSQAAQ. Over 92% of participants agreed or strongly agreed with each of the remaining mSQAAQ items.
Conclusion
The lebrikizumab prefilled pen demonstrated high reported ease of use and user confidence in adults with AD following a trained, simulated injection.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Southern California Dermatology, Santa Ana, CA, USA.
- Harbor University of California Los Angeles, Torrance, CA, USA.
- Concentrics Center for Research, Indianapolis, IN, USA.
- StracSkin, PLLC, Portsmouth, NH, USA.
- Optima Dermatology, Portsmouth, NH, USA.
- Cutaneous Clinical Trials, LLC of Beverly, Beverly, MA, USA.
Zitieren
APA
Soung, J., Miller, W., Jarell, A. D., Greenstein, D., DeLuca-Carter, L., Crane, H. M., Behling, M., Duffy, K., Pierce, E., & Shahriari, M. (2026). Ease of Use of the Lebrikizumab Prefilled Pen for Individuals with Atopic Dermatitis. Patient Preference and Adherence, Volume 20, 1-9. https://doi.org/10.2147/ppa.s612056
Vancouver
Soung J, Miller W, Jarell AD, Greenstein D, DeLuca-Carter L, Crane HM, et al. Ease of Use of the Lebrikizumab Prefilled Pen for Individuals with Atopic Dermatitis. Patient Preference and Adherence. 2026;Volume 20:1-9. doi:10.2147/ppa.s612056
BibTeX
@article{Soung2026,
author = {Soung, Jennifer and Miller, William and Jarell, Abel D and Greenstein, David and DeLuca-Carter, Louise and Crane, Heidi M and Behling, Michael and Duffy, Kevin and Pierce, Evangeline and Shahriari, Mona},
title = {Ease of Use of the Lebrikizumab Prefilled Pen for Individuals with Atopic Dermatitis},
journal = {Patient Preference and Adherence},
year = {2026},
volume = {Volume 20},
pages = {1--9},
doi = {10.2147/ppa.s612056}
}
EUVIMED